Inside a compounded GLP-1 order: from prescription to doorstep
A patient sees a form, a confirmation, and a box. Between those three moments are seven handoffs across four regulated parties — and a well-built program surfaces every one of them to the patient and to your product.
Lithos Staff
Photograph via UnsplashA compounded GLP-1 order moves through intake and identity verification, clinician review and prescribing, electronic prescription routing to a licensed pharmacy, compounding and quality release, cold-chain shipping, delivery, and the refill cycle. Each stage is owned by a different party (brand, medical group, pharmacy, carrier) and each emits a status your product should show the patient. Typical elapsed time from checkout to delivery is three to seven days; most of the variance is in pharmacy queue and carrier transit, not clinical review.
Stage 1 — Intake and identity
The patient completes a structured medical intake: history, medications, allergies, weight and height, contraindication screening, and, for GLP-1 programs, the questions that determine eligibility and starting dose. Identity is verified (identity proofing) and telehealth consent is captured in the form the patient’s state requires. A rules layer checks state modality rules and product availability before anything is submitted. Your product sees: patient created, care plan opened, encounter submitted.
Stage 2 — Clinician review
A clinician licensed in the patient’s state picks up the encounter from a queue. For async-eligible cases they review the intake, ask follow-up questions through secure messaging if needed, and document a note that shows what was considered. If the case needs a live visit — by state rule or clinical judgment — it is escalated. Labs may be ordered before or alongside the first prescription depending on protocol. Your product sees: encounter in review, clinician message (if any), encounter completed with a decision.
Stage 3 — The prescription
On approval, the clinician writes the prescription electronically under their own NPI: drug, strength, quantity, directions, refills, and the compounding rationale the patient-specific pathway calls for. The eRx is transmitted via NCPDP SCRIPT or a direct pharmacy integration. Your product sees: prescription created.
Stage 4 — Pharmacy routing
Before transmission, the order is matched to a pharmacy on the bench that is licensed for the patient’s state (non-resident license), stocks the product, and currently has the best turnaround for that region. A program with two to four pharmacies and automated routing rarely has an order stuck; a program with one pharmacy inherits every queue and every licensure gap that pharmacy has. Your product sees: order created, pharmacy assigned.
Stage 5 — Compounding and release
The pharmacy verifies the prescription, compounds the preparation (or fills from anticipatory stock where permitted), assigns a lot and beyond-use date, performs its release checks, and packages for cold chain. This is where most elapsed time lives: one to three days depending on queue, sterile-compounding capacity, and whether the pharmacy batches by day. Your product sees: order accepted, order filled (with lot and BUD where the pharmacy provides them).
Stage 6 — Shipping and delivery
Refrigerated injectables ship in insulated packaging with cold packs via expedited carriers, typically Monday through Wednesday to avoid weekend dwell. Tracking is attached to the order; delivery exceptions (weather, missed handoffs) are the most common patient-support driver in a GLP-1 program, so surface them proactively. Your product sees: order shipped with tracking, out for delivery, delivered.
Stage 7 — The refill cycle
GLP-1 programs are monthly by construction because titration is monthly. Before the next shipment, the patient completes a short check-in (weight, side effects, adherence, any new medications), a clinician reviews it and decides to continue, hold, or step the dose, and a new prescription and order are generated. The check-in can be prompted automatically; the decision stays with a clinician. Your product sees: a new encounter, prescription, and order — the same events as the first cycle.
The whole pipeline, with who owns what
| Stage | Owner | Typical time | Status your product shows |
|---|---|---|---|
| Intake and identity | Brand (front-end) + infrastructure (rules) | Minutes | “Submitted for clinician review” |
| Clinician review | Medical group | Hours to 1 day | “Reviewed — approved” / message |
| Prescription | Medical group | Minutes | “Prescription sent to pharmacy” |
| Pharmacy routing | Infrastructure | Minutes | “Pharmacy: [name], [state]” |
| Compounding and release | Pharmacy | 1–3 days | “Being prepared” |
| Shipping | Pharmacy + carrier | 1–2 days | Tracking, “out for delivery” |
| Refill | All of the above, monthly | Same cycle | “Check-in due” → repeat |
The brand owns the promise and the experience around it. The medical group owns the clinical decisions. The pharmacy owns the product. Infrastructure owns the handoffs — and the handoffs are where orders get lost when nobody owns them.
Frequently asked questions
How long does a compounded GLP-1 order take to arrive?
Commonly three to seven days from checkout. Clinician review is often same-day; pharmacy compounding and quality release take one to three days depending on queue; cold-chain shipping is one to two days. Programs that route to pharmacies by region and turnaround land at the low end.
Why does the order need cold-chain shipping?
Compounded semaglutide and tirzepatide are typically dispensed as refrigerated injectables. Pharmacies ship in insulated packaging with cold packs and use expedited carriers so the product stays within its temperature range in transit.
What happens if the clinician declines the prescription?
The encounter closes with a documented reason, the patient is notified with next steps (more information, a live visit, or a referral), and any payment for medication is not captured or is refunded, depending on how the program sequences payment. The visit itself may still be charged.
How do refills work for GLP-1 programs?
Most programs run a monthly cycle aligned to the titration schedule: a brief check-in encounter (weight, side effects, adherence), a clinician decision to continue or adjust the dose, a new prescription, and a fresh pharmacy order. Automating the check-in and the reorder while keeping a clinician in the decision is what makes retention work.
From first call to first patient, in weeks.
A 15-minute intro call, sandbox credentials the same day, go-live in 3–4 weeks — new launches and existing patient bases alike.